MURR Opens Global Access to NCA Lutetium-177, Producing Year-Round Supply
MURR became the first U.S. reactor to offer GMP no-carrier-added Lu-177 globally, producing the cancer-fighting isotope 52 weeks a year for research and commercial buyers.
The University of Missouri Research Reactor has opened its no-carrier-added Lutetium-177 to the global marketplace, marking the first time MURR's GMP NCA Lu-177 product will be available to buyers outside the United States. The announcement, made March 9, extends year-round production of the medical isotope to research, clinical, and commercial customers worldwide.
MURR had already established itself as the premier U.S. supplier of Lu-177 over the past several years, but the domestic focus leaves a significant portion of demand unaddressed. The GMP product is produced 52 weeks per year, a continuous cadence that positions MURR to reliably supply international customers without seasonal gaps.
Executive Director Matt Sanford framed the expansion around the accelerating pipeline of targeted cancer treatments. "There is a growing demand for Lutetium-177 for research, clinical trials and commercial products as more cancer fighting drugs are developed," Sanford said. "MURR is the only end-to-end producer of Lu-177 in the United States, and we are expanding our focus. In addition to supplying commercial quantities of NCA Lu-177 for use in FDA-approved drugs, we will now meet the needs of researchers and clinical-stage companies."
The clinical case for Lu-177 centers on its mechanism. Lutetium-177 is a reactor-produced medical radioisotope that has proven effective in targeted cancer therapies; radiopharmaceuticals containing it deliver precise, high-energy radiation directly to tumors by emitting therapeutic beta particles. The no-carrier-added designation matters here because NCA Lu-177 contains minimal stable lutetium isotope contamination, maximizing specific activity and making it particularly valuable in high-precision radiopharmaceutical manufacturing.
By positioning itself as the sole end-to-end U.S. producer and now opening that supply chain internationally, MURR is staking out a central role in what Sanford described as a growing global demand curve. Researchers at early clinical stages and established commercial manufacturers alike will now be able to source GMP NCA Lu-177 directly from the Columbia, Missouri reactor, with production running through every week of the calendar year.
This article was produced by Prism’s automated news system from verified source data, official records, and press releases, then run through automated quality and moderation checks before publishing. The system is built and supervised by the people who set the standards it runs under. Read our full AI policy.
Did this article answer your question?
